Needham Maintains Buy on TransMedics Group, Lowers Price Target to $142
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $174 to $142.
Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $174 to $142.